Interim Safety and Efficacy Results from Phase 1/2 Study of Mecbotamab Vedotin (BA3011), a CAB-AXL-ADC, in Patients with Advanced Sarcoma
Protein-associated Chemical Switches Differentially Modulate the Binding Activities of Human Apolipoprotein E Isoforms with Their Receptors and with Amyloid Beta Peptides.
Novel Conditionally Active Bispecific T Cell Engagers Targeting Solid Tumors
Novel Conditionally Active Bispecific EpCAM x CD3 T Cell Engagers Targeting Solid Tumors
